U.S. Stem Cell, Inc.

Equities

USRM

US90350U1007

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:42:59 02/05/2024 BST			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		0.00%	0.00%

2023	U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
2023	U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	CI

U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021

March 31, 2022 at 08:35 pm

U.S. Stem Cell, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported revenue was USD 0.200749 million compared to USD 0.277087 million a year ago. Net loss was USD 3.29 million compared to USD 2.89 million a year ago.

Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.

Latest news about U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	14/04/23	CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	13/04/23	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/11/22	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	23/05/22	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	31/03/22	CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	30/03/22	CI
U.S. Stem Cell, Inc. Announces Management Changes	09/03/22	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	09/11/21	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	12/08/21	CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	15/07/21	CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	15/07/21	CI
U.S. Stem Cell, Inc.'s Equity Buyback announced on January 16, 2015, has expired.	30/12/20	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	06/11/19	CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.	06/11/19	CI
U.S. Stem Cell, Inc. Announces Resignation of Kristin Comella as a Member of the Board of Directors and Her Position as Chief Scientific Officer	06/09/19	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	07/08/19	CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.	07/08/19	CI
U.S. Stem Cell, Inc. Announces Earnings Results for the First Ended March 31, 2019	07/05/19	CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.	07/05/19	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2018	13/03/19	CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.	13/03/19	CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	12/03/19	CI
U.S. Stem Cell, Inc. Announces Revenue Results for the Quarter and Financial Results for the Nine Months Ended September 30, 2018	07/11/18	CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.	07/11/18	CI
U.S. Stem Cell, Inc. Appoints Phil Posa as Senior Vice President of U.S. & International Sales	11/09/18	CI

Chart U.S. Stem Cell, Inc.

Duration

Period

More charts

Company Profile

U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector. Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
U.S. STEM CELL, INC.	0.00%	661
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	106B
ARGENX SE	+7.02%	23.47B
BIONTECH SE	-14.60%	21.9B
GENMAB A/S	-7.05%	18.77B
WUXI APPTEC CO., LTD.	-38.55%	17.85B
BEIGENE, LTD.	-8.83%	16.78B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	14.41B
SAREPTA THERAPEUTICS, INC.	+37.49%	12.86B
VIKING THERAPEUTICS, INC.	+329.39%	8.78B

Bio Therapeutic Drugs